Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada. more
Time Frame | BIVI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -18.9% | -0.94% | -2.6% |
1-Month Return | -31.33% | -5.08% | -1.08% |
3-Month Return | -26.43% | -10.62% | 3.45% |
6-Month Return | -56.54% | -6.18% | 8.57% |
1-Year Return | -84.15% | 1.98% | 24.3% |
3-Year Return | -95.89% | -0.93% | 25.58% |
5-Year Return | -95.15% | 33.84% | 84.07% |
10-Year Return | -99.43% | 102.52% | 185.12% |
Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Cost of Revenue | 229.38K | 229.38K | 237.42K | 266.84K | 229.38K | [{"date":"2020-06-30","value":85.96,"profit":true},{"date":"2021-06-30","value":85.96,"profit":true},{"date":"2022-06-30","value":88.97,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":85.96,"profit":true}] |
Gross Profit | (229.38K) | (229.38K) | (237.42K) | (266.84K) | (229.38K) | [{"date":"2020-06-30","value":-22937700,"profit":false},{"date":"2021-06-30","value":-22937700,"profit":false},{"date":"2022-06-30","value":-23742100,"profit":false},{"date":"2023-06-30","value":-26684200,"profit":false},{"date":"2024-06-30","value":-22937700,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Operating Expenses | 2.69M | 138.05M | 27.25M | 45.08M | 31.95M | [{"date":"2020-06-30","value":1.95,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":19.74,"profit":true},{"date":"2023-06-30","value":32.65,"profit":true},{"date":"2024-06-30","value":23.14,"profit":true}] |
Operating Income | (2.69M) | (138.05M) | (27.25M) | (45.08M) | (32.18M) | [{"date":"2020-06-30","value":-269288800,"profit":false},{"date":"2021-06-30","value":-13805413900,"profit":false},{"date":"2022-06-30","value":-2725297700,"profit":false},{"date":"2023-06-30","value":-4508044800,"profit":false},{"date":"2024-06-30","value":-3217958500,"profit":false}] |
Total Non-Operating Income/Expense | (18.76M) | 7.27M | (950.40K) | (8.91M) | - | [{"date":"2020-06-30","value":-258.08,"profit":false},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":-13.08,"profit":false},{"date":"2023-06-30","value":-122.65,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Pre-Tax Income | (16.68M) | (130.25M) | (26.08M) | (50.26M) | (32.12M) | [{"date":"2020-06-30","value":-1667676900,"profit":false},{"date":"2021-06-30","value":-13024920400,"profit":false},{"date":"2022-06-30","value":-2608446800,"profit":false},{"date":"2023-06-30","value":-5025581500,"profit":false},{"date":"2024-06-30","value":-3212053300,"profit":false}] |
Income Taxes | 4.77M | 559.46K | (3.29M) | 4.30M | (229.38K) | [{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":11.72,"profit":true},{"date":"2022-06-30","value":-68.88,"profit":false},{"date":"2023-06-30","value":90.1,"profit":true},{"date":"2024-06-30","value":-4.81,"profit":false}] |
Income After Taxes | (21.45M) | (130.81M) | (22.80M) | (54.56M) | - | [{"date":"2020-06-30","value":-2144919700,"profit":false},{"date":"2021-06-30","value":-13080865900,"profit":false},{"date":"2022-06-30","value":-2279705000,"profit":false},{"date":"2023-06-30","value":-5455596500,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Income From Continuous Operations | (16.68M) | (130.25M) | (26.08M) | (50.26M) | - | [{"date":"2020-06-30","value":-1667676900,"profit":false},{"date":"2021-06-30","value":-13024920400,"profit":false},{"date":"2022-06-30","value":-2608446800,"profit":false},{"date":"2023-06-30","value":-5025581500,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Net Income | (21.45M) | (183.85M) | (26.08M) | (50.26M) | (32.12M) | [{"date":"2020-06-30","value":-2144919700,"profit":false},{"date":"2021-06-30","value":-18384700000,"profit":false},{"date":"2022-06-30","value":-2608446800,"profit":false},{"date":"2023-06-30","value":-5025581400,"profit":false},{"date":"2024-06-30","value":-3212053300,"profit":false}] |
EPS (Diluted) | (7.52) | (13.90) | (1.12) | (1.56) | (1.53) | [{"date":"2020-06-30","value":-752,"profit":false},{"date":"2021-06-30","value":-1390,"profit":false},{"date":"2022-06-30","value":-112,"profit":false},{"date":"2023-06-30","value":-156,"profit":false},{"date":"2024-06-30","value":-152.82,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BIVI | |
---|---|
Cash Ratio | 2.93 |
Current Ratio | 2.95 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BIVI | |
---|---|
ROA (LTM) | -66.69% |
ROE (LTM) | -208.26% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BIVI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.34 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.66 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BIVI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.63 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Biovie Inc (BIVI) share price today is $2.06
Yes, Indians can buy shares of Biovie Inc (BIVI) on Vested. To buy Biovie Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BIVI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Biovie Inc (BIVI) via the Vested app. You can start investing in Biovie Inc (BIVI) with a minimum investment of $1.
You can invest in shares of Biovie Inc (BIVI) via Vested in three simple steps:
The 52-week high price of Biovie Inc (BIVI) is $18.9. The 52-week low price of Biovie Inc (BIVI) is $1.04.
The price-to-earnings (P/E) ratio of Biovie Inc (BIVI) is
The price-to-book (P/B) ratio of Biovie Inc (BIVI) is 2.63
The dividend yield of Biovie Inc (BIVI) is 0.00%
The market capitalization of Biovie Inc (BIVI) is $36.96M
The stock symbol (or ticker) of Biovie Inc is BIVI